Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.11
- Piotroski Score 4.00
- Grade Buy
- Symbol (LGVN)
- Company Longeveron Inc.
- Price $1.90
- Changes Percentage (1.33%)
- Change $0.03
- Day Low $1.82
- Day High $1.92
- Year High $23.90
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $10.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$9.60
- Trailing P/E Ratio -0.11
- Forward P/E Ratio -0.11
- P/E Growth -0.11
- Net Income $-21,413,000
Income Statement
Quarterly
Annual
Latest News of LGVN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Longeveron Inc. (LGVN) Stock Price, News, Quote & History
Longeveron Inc. is a biotech company in the US and Japan focusing on cellular therapies for aging-related and life-threatening conditions. Their key product is LOMECEL-B, derived from young adult dono...
By Yahoo! Finance | 3 months ago
